ESC 365 - Effects of Angiotensin Receptor/Neprilysin Inhibitor Therapy on NT-proBNP and Cardiac Remodeling in Heart Failure with Reduced Ejection Fraction: Primary Results of the PROVE-HF Study

ESC Premium Access

Effects of Angiotensin Receptor/Neprilysin Inhibitor Therapy on NT-proBNP and Cardiac Remodeling in Heart Failure with Reduced Ejection Fraction: Primary Results of the PROVE-HF Study

Session: Late Breaking Science in Heart Failure 1

Topic: Pharmacotherapy

Speaker: Professor J. Januzzi (Boston, US)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor James Januzzi

Massachusetts General Hospital - Harvard Medical School, Boston (United States of America)

37 presentations

11 followers

4 more presentations in this session

Spironolactone in atrial fibrillation with preserved cardiac contractility

Speaker: Doctor E. Shantsila (Liverpool, GB)

Effects of Sacubitril-Valsartan Compared with Enalapril on Arterial Hemodynamics and Cardiac Remodeling in Patients with Heart Failure and Reduced Ejection Fraction

Speaker: Doctor A. Desai (Boston, US)

Clinical effectiveness of primary prevention implantable defibrillators: results of the EU-CERT-ICD non-randomised, controlled, multicentre study

Speaker: Associate Professor M. Zabel (Goettingen, DE)

Clinical phenotypes, gender differences and adverse events associated with truncating variants in the Titin (TTN) gene

Speaker: Doctor M. Akhtar (London, GB)

Access the full session

Late Breaking Science in Heart Failure 1

Speakers: Professor J. Januzzi, Doctor E. Shantsila, Doctor A. Desai, Associate Professor M. Zabel, Doctor M. Akhtar

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources